Showing 2891-2900 of 4063 results for "".
- Johnson & Johnson Vision Highlights New Data at 2018 ARVO Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-highlights-new-data-at-2018-arvo-annual-meeting/2480201/Johnson & Johnson Vision announced that a suite of new research from its eye health portfolio will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaii from April 29 to M
- ARVO 2018: Genentech Ophthalmology Data Highlightshttps://modernod.com/news/arvo-2018-genentech-ophthalmology-data-highlights/2480204/Genentech will be presenting several studies at the Association for Research in Vision and Ophthalmology (ARVO) meeting on April 29 – May 3 in Honolulu. Data being reported at ARVO continue to show the safety and efficacy of Lucentis (ranibizumab) as a treatment for wet age-related macular degene
- Novaliq to Present Scientific and Clinical Research During the 2018 ARVO Meeting in Honoluluhttps://modernod.com/news/novaliq-to-present-scientific-and-clinical-research-during-the-2018-arvo-meeting-in-honolulu/2480208/Novaliq announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu, Hawaii (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With th
- Market Scope: China’s Ophthalmic Market to grow 11.3% to $4.5 Billion in 2023https://modernod.com/news/market-scope-chinas-ophthalmic-market-to-grow-11-3-to-4-5-billion-in-2023/2480211/Market Scope forecasts that China’s $2.6 billion ophthalmic market will grow at a compound annual rate of 11.3 percent over the next 5 years to $4.5 billion in 2023. China has tremendous unmet need for ophthalmic care. The country is home to approximately one-third of the world’s blind peo
- Data from BioTime’s OpRegen and Retinal Restoration Programs to Be Presented at ARVO 2018https://modernod.com/news/data-from-biotimes-opregen-and-retinal-restoration-programs-to-be-presented-at-arvo-2018/2480231/BioTime announced that data from the ongoing OpRegen clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29 – May 3, 2018, in Honolulu, Hawaii. The scheduled times (note
- American Academy of Optometry 2018 San Antonio Education Program Announcedhttps://modernod.com/news/american-academy-of-optometry-2018-san-antonio-education-program-announced/2480235/The American Academy of Optometry is pleased to announce highlights of the education program taking place at Academy 2018 San Antonio, November 7-10, 2018. The annual meeting offers a wide array of clinically relevant CE courses and cutting-edge research in the clinical and vision sciences. Atten
- Shire Announces Sale of Oncology Business to Servier for $2.4 Billionhttps://modernod.com/news/shire-announces-sale-of-oncology-business-to-servier-for-2-4-billion/2480237/Shire announced that it has entered into a definitive agreement with privately held French pharmaceutical group Servier S.A.S. to sell its Oncology business for $2.4 billion. “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the
- Thomas W. Samuelson, MD, Named 2018 ASCRS Presidenthttps://modernod.com/news/thomas-w-samuelson-md-named-2018-ascrs-president/2480251/Thomas W. Samuelson, MD, a world-renowned ophthalmologist who specializes in the medical and surgical treatment of glaucoma and disorders of the anterior segment, will assume his role as president of the American Society of Cataract and Refractive Surgery (ASCRS) in April 2018. He currently serve
- FDA Issues Warning Letter to Imprimis for False and Misleading Claimshttps://modernod.com/news/fda-issues-warning-letter-to-imprimis-for-false-and-misleading-claims/2480271/The FDA has issued a warning letter to Imprimis Pharmaceuticals, claiming the maker of compounded drugs made false or misleading claims about its products. The FDA stated that Imprimis made misleading claims regarding its “
- Global Dry Eye Treatment Revenues to Grow to $4.9 Billion by 2022https://modernod.com/news/global-dry-eye-treatment-revenues-to-grow-to-49-billion-by-2022/2480272/Market Scope expects the global dry eye treatments market to grow at a healthy pace through 2022, as 2017 revenues of $3.7 billion climb to $4.9 billion. Revenues will climb most sharply in emerging markets and other developing nations where we forecast double-digit compounded annual growth rates